Profile data is unavailable for this security.
About the company
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.
- Revenue in USD (TTM)25.18m
- Net income in USD-22.29m
- Incorporated2007
- Employees101.00
- LocationCapricor Therapeutics Inc8840 Wilshire Blvd, 2nd FloorBEVERLY HILLS 90211United StatesUSA
- Phone+1 (310) 358-3200
- Fax+1 (302) 655-5049
- Websitehttps://capricor.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Achieve Life Sciences Inc | 0.00 | -29.82m | 150.37m | 22.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | -0.0684 | 0.00 | -- | -- | 0.00 | -120.85 | -86.31 | -860.46 | -119.59 | -- | -- | -- | -- | -- | -10.66 | 1.10 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Regulus Therapeutics Inc | 0.00 | -30.04m | 150.57m | 30.00 | -- | 2.20 | -- | -- | -1.59 | -1.59 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -77.55 | -53.74 | -104.84 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.0592 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| ASP Isotopes Inc | 433.03k | -16.29m | 155.09m | 76.00 | -- | 9.52 | -- | 358.14 | -0.5016 | -0.5016 | 0.0131 | 0.3331 | 0.0216 | -- | -- | 5,697.76 | -81.39 | -- | -109.02 | -- | 32.09 | -- | -3,762.82 | -- | -- | -251.76 | 0.0378 | -- | -- | -- | -229.34 | -- | -- | -- |
| ProQR Therapeutics NV | 10.16m | -29.99m | 157.83m | 157.00 | -- | 3.70 | -- | 15.54 | -0.3703 | -0.3703 | 0.1254 | 0.524 | 0.0616 | -- | 0.332 | 64,703.02 | -17.94 | -35.51 | -21.82 | -40.51 | -- | -- | -291.18 | -926.31 | -- | -- | 0.3229 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Greenwich Lifesciences Inc | 0.00 | -8.89m | 159.95m | 3.00 | -- | 23.82 | -- | -- | -0.6921 | -0.6921 | 0.00 | 0.5215 | 0.00 | -- | -- | 0.00 | -86.87 | -36.43 | -89.30 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Gossamer Bio Inc | 0.00 | -179.82m | 160.62m | 135.00 | -- | 2.55 | -- | -- | -1.38 | -1.38 | 0.00 | 0.2785 | 0.00 | -- | -- | 0.00 | -61.54 | -57.43 | -74.38 | -64.38 | -- | -- | -- | -- | -- | -15.09 | 0.769 | -- | -- | -- | 21.61 | -- | -- | -- |
| Scpharmaceuticals Inc | 13.59m | -54.81m | 161.16m | 135.00 | -- | 4.32 | -- | 11.86 | -1.42 | -1.42 | 0.353 | 1.03 | 0.1243 | 0.7569 | -- | 100,688.90 | -50.13 | -38.23 | -55.33 | -42.31 | 71.96 | -- | -403.22 | -1,360.16 | 6.40 | -18.35 | 0.5105 | -- | -- | -- | -48.79 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -62.57m | 164.61m | -- | -- | -- | -- | -- | -0.4043 | -0.4043 | 0.00 | -0.5867 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.74 | 42.99 | -- | -- | -- | -41.32 | -- | -- | -- |
| Capricor Therapeutics Inc | 25.18m | -22.29m | 166.02m | 101.00 | -- | 7.26 | -- | 6.59 | -0.8708 | -0.8708 | 0.9403 | 0.7256 | 0.4627 | -- | 4.61 | 249,287.80 | -40.96 | -54.12 | -82.59 | -75.13 | -- | -- | -88.52 | -316.25 | -- | -- | 0.13 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Kodiak Sciences Inc | 0.00 | -260.49m | 168.64m | 111.00 | -- | 0.6342 | -- | -- | -4.97 | -4.97 | 0.00 | 5.06 | 0.00 | -- | -- | 0.00 | -45.46 | -31.73 | -49.53 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| bluebird bio Inc | 21.73m | -91.17m | 168.86m | 323.00 | -- | 0.4266 | -- | 7.77 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
| P3 Health Partners Inc | 1.27bn | -57.77m | 169.70m | 400.00 | -- | 0.4407 | -- | 0.134 | -0.6494 | -0.6494 | 13.37 | 1.22 | 1.46 | -- | 13.23 | 3,165,938.00 | -21.46 | -- | -96.06 | -- | 2.50 | 0.1781 | -14.72 | -56.93 | -- | -10.33 | 0.1999 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Alpha Tau Medical Ltd | 0.00 | -29.16m | 174.18m | 121.00 | -- | 2.06 | -- | -- | -0.4203 | -0.4203 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -25.63 | -- | -26.99 | -- | -- | -- | -- | -- | -- | -- | 0.0623 | -- | -- | -- | 13.64 | -- | -- | -- |
| Mediwound Ltd | 18.69m | -6.72m | 176.64m | 100.00 | -- | 5.43 | -- | 9.45 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
Data as of May 01 2024. Currency figures normalised to Capricor Therapeutics Inc's reporting currency: US Dollar USD
10.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.16m | 3.68% |
| Woodline Partners LPas of 31 Dec 2023 | 909.54k | 2.90% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 355.73k | 1.13% |
| Geode Capital Management LLCas of 31 Dec 2023 | 316.20k | 1.01% |
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 149.12k | 0.48% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 146.32k | 0.47% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 127.23k | 0.41% |
| American Portfolios Advisors, Inc.as of 31 Dec 2023 | 107.55k | 0.34% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 85.22k | 0.27% |
| LPL Financial LLCas of 31 Dec 2023 | 78.24k | 0.25% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
